RxDoctor Payments Data

Michael James

Nurse Practitioner · Carbondale, ILNPI 1659004430

Payments from drug & device makers

$9,511in general payments, 2019–2025

Across 319 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$2K
  • Madrigal Pharmaceuticals$556
  • Takeda Pharmaceuticals U.S.A., Inc.$538
  • Ardelyx, Inc.$437
  • Intercept Pharmaceuticals, Inc.$435
  • plus $3K from 18 others

What the payments were for

  • Food & beverage$9,17196%
  • Education$3404%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,511 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$59,720
Medicare patients
517
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab72$1,954,082
OcalivaObeticholic Acid16$149,941
CreonLipase/Protease/Amylase33$129,245
LinzessLinaclotide165$117,836
XifaxanRifaximin29$111,819
RinvoqUpadacitinib15$96,976
Humira(Cf) PenAdalimumab13$88,550
IbsrelaTenapanor Hcl44$77,446
ZenpepLipase/Protease/Amylase18$66,706
ViberziEluxadoline17$42,108
TrulancePlecanatide28$21,167
Mesalamine35$13,044
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates182$11,357
Ursodiol48$8,549
Pantoprazole Sodium582$7,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,741$1,954,08272 claims
AbbVieCreon, Linzess, Rinvoq, Viberzi$3,168$386,166230 claims
Intercept Pharmaceuticals, Inc.Ocaliva$435$149,94116 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$375$132,98657 claims
Ardelyx, Inc.Ibsrela$437$77,44644 claims
Aimmune Therapeutics, Inc.Zenpep$79$66,70618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Carbondale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →